Charles Riv Labs Intl Inc: (NYSE: CRL)

$45.35

0.79 (1.77%)

Volume 626,693

May 14 04:02 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.27%
#2	Buy	18.43%
#3	Hold	9.86%
#4	Sell	4.09%
#5	Strong Sell	1.87%
S&P	500	9.59%

Overview Quote

            Stock Activity
        
		Day Low - High
		44.37 - 45.39
	
		52wk Low - High
		31.48 - 46.90
	
		Previous Close
		44.56
	
		Avg. Volume
		482,646
	
		Industry
		MEDICAL SERVICES
	
		Market Cap
		2.15 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.16
	
		PE (Forward)
		15.85
	
		Current Year Est.
		2.81
	
		Quarterly Earnings ESP 
		-1.37%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.27%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.43%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        9.86%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.09%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        1.87%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.59%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		103 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            15.85
                        
                            PEG Ratio
                            1.93
                        
                            Current Year Est.
                            2.81
                        
                            Current Quarter Estimate
                            0.73
                        
                            Most Accurate Estimate
                            0.72
                        
                            Earnings ESP 
                            -1.37%
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            2.73
                        
                            Expected Earnings Growth
                            8.22%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years.   
Full CRL Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
CRL Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.73	0.69	2.81	3.08
Number of Estimates	11	10	11	11
Low Estimate	0.69	0.67	2.77	2.98
High Estimate	0.80	0.73	2.85	NA
Year Ago EPS	0.75	0.65	2.74	2.81
EPS Growth	-2.42%	6.92%	2.62%	9.38%

More CRL Estimates

Average Earnings Estimates for CRL

EPS Growth for CRL

Industry Analysis

Name	Symbol	Previous Close
CHARLES RVR LAB	CRL	44.56
COVANCE INC	CVD	76.31
ICON PLC	ICLR	33.01
IPC THE HOSPITL	IPCM	48.48
OMNICARE INC	OCR	45.32
PAREXEL INTL CP	PRXL	45.07
ADVISORY BOARD	ABCO	49.64
BG MEDICINE INC	BGMD	1.67
CATAMARAN CORP	CTRX	51.22
EXPRESS SCRIPTS	ESRX	61.94

Sector:Medical>> Industry:MEDICAL SERVICES

COMPARE TICKER vs. Its Peers

Zacks Commentary

ABCO Posts Solid 4Q and FY2013 Earnings

May 13, 2013

Charles River Misses Estimates in 1Q

May 02, 2013

Mixed 4Q for Charles River

Feb 14, 2013

Charles River Acquires Vital River

Jan 08, 2013

BASi Introduces Culex NxT

Jan 03, 2013

Charles River 2013 EPS Guidance Lags

Dec 13, 2012

Earnings Beat at Charles River

Oct 31, 2012

CRL/AstraZeneca Join Forces

Oct 19, 2012

More CRL Zacks Commentary

Financials

EPS TTM	2.73
Sales	1,130
Net Income	96
Price/Earnings	16.32
Price/Book	3.40
Price/Cash Flow	9.35
Price/Sales	1.89

More CRL Financials

News

Charles River reports lower Q1 net income, reaffirms guidance for 2013 - Datamonitor

May 13, 2013

Charles River Laboratories International (CRL) Showing Bullish Technicals But Could Break Through $44.27 Resistance - Freshbrewedmedia

May 10, 2013

Shares of ICON Underperformed its Peers in the Life Sciences Tools & Services Industry (ICLR, PRXL, LIFE, CRL, QGEN) - Financial News Network Online - News Corner

May 7, 2013

Charles River Laboratories Posts First Quarter 2013 Results - Close-Up Media

May 6, 2013

Charles River Laboratories to Present at Baird's Growth Stock Conference - Businesswire

May 6, 2013

Top 5 Companies in the Life Sciences Tools & Services Industry with the Best Relative Performance (MTD, BDSI, CRL, PKI, PRXL) - Financial News Network Online - News Corner

May 6, 2013

Charles River Laboratories had the Lowest Relative Performance in the Life Sciences Tools & Services Industry (CRL, CVD, PKI, QGEN, BRKR) - Financial News Network Online - News Corner

May 3, 2013

Cramer`s Top Stock Picks: AGN BP CRL PRU AIG - TheStreet.com

May 3, 2013

See All News Stories on CRL

Broker Recommendations

Current ABR	2.45
ABR (Last Week)	2.45
# of recs in ABR	11
Average Target Price	45.40
Industry Rank by ABR	103 out of 265
Rank in Industry	13 out of 15

More CRL Broker Recommendations

Day Low - High	44.37 - 45.39
52wk Low - High	31.48 - 46.90
Previous Close	44.56
Avg. Volume	482,646
Industry	MEDICAL SERVICES
Market Cap	2.15 B
Div - Yield	0.00 - 0.00
Beta	1.16
PE (Forward)	15.85
Current Year Est.	2.81
Quarterly Earnings ESP	-1.37%

PE (Forward)	15.85
PEG Ratio	1.93
Current Year Est.	2.81
Current Quarter Estimate	0.73
Most Accurate Estimate	0.72
Earnings ESP	-1.37%
Next Earnings Report Date	08-06-2013
EPS Last Year	2.73
Expected Earnings Growth	8.22%

Username: Password:

Remember me [?]

Charles Riv Labs Intl Inc: (NYSE: CRL)

$45.35

0.79 (1.77%)

Volume 626,693

May 14 04:02 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MEDICAL SERVICES

Zacks Commentary

Financials

News

Broker Recommendations